GlassScriptPhysician profile
Jenna L Green
NPI 1437524519
$2,811.25
in general payments reported to CMS, 2019-2025
28 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $732 · 2023: $582 · 2024: $234 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $604.55 | 2021-2025 | |
| Novo Nordisk INC | $541.16 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $217.15 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.22 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $159.83 | 2021-2025 | Airsupra |
| Glaxosmithkline, LLC. | $131.93 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $122.34 | 2021-2023 | |
| Inspire Medical Systems, INC. | $111.49 | 2023 | Inspire |
| Astellas Pharma US INC | $88.10 | 2021-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $71.62 | 2022 | |
| Lilly USA, LLC | $63.95 | 2022-2024 | Jardiance, Emgality |
| Genentech USA, INC. | $62.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $55.12 | 2023-2025 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $45.49 | 2022-2024 | |
| Exact Sciences Corporation | $38.78 | 2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $33.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.16 | 2023 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $32.75 | 2021 | |
| Axsome Therapeutics, INC. | $31.44 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $30.34 | 2022 | |
| Sumitomo Pharma America, INC. | $23.37 | 2023 | Gemtesa |
| Vbi Vaccine (Delaware) INC. | $20.40 | 2023 | Prehevbrio |
| Corcept Therapeutics | $19.77 | 2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $17.47 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.35 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.76 | 2021 | |
| Merck Sharp & Dohme LLC | $13.68 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Seqirus USA INC | $13.30 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.